COA library

Scope of this report

Applies only to the sample, batch, and analyses stated in the document. Identity by LC-MS, purity by HPLC-UV.

Scope of this report

Reports net content only. This report does not show a purity result.

Scope of this report

Identity confirmed by LC-MS, purity by HPLC-UV, appearance recorded as white lyophilized powder. Net content is 11.12 mg against the 10 mg on the label. The vials photographed on the certificate carry the same lot, MOQU, and the same 10 mg fill as the product sold. One sample was tested, and the document reports no endotoxin or microbial figure. It supersedes the Chromate / Evolve BioPep report for batch EVOLVE6YLUG9, which covered a different lot and is no longer published here.

Scope of this report

Covers identity and purity only. Net content was recorded as Not Requested and is not established by this report.

Scope of this report

Two vials were tested and both results are shown as reported; they are not averaged. Applies only to the samples, batch, and analyses stated in the document.

Scope of this report

Covers peptide purity by HPLC-UV at 274 nm and a microbial screen, both recorded as Pass. The certificate names the analyte as CJC-1295 and does not distinguish the DAC-modified form from the non-DAC form sold here. Net content was not determined.

Scope of this report

Covers peptide purity by HPLC-UV at 220 nm and a microbial screen, both recorded as Pass. The certificate also prints a By Mass figure whose basis the laboratory has not confirmed, so no net content is stated here.

Scope of this report

Purity is printed as 100% and is reproduced exactly as printed rather than rounded or restated. The document records no detection wavelength and no mass determination for this sample. The microbial screen is recorded as Pass.

Scope of this report

Identity by LC-MS, reported as Tirzepatide at 4812.8 Da. Endotoxins reported below 2.5 EU per vial. Two samples were tested and both results are shown as printed rather than averaged; note that both exceed the 15mg labelled content. The certificate was issued to a third party rather than commissioned by ASCND Research, and that party's contact detail is redacted on the published scan. Nothing else on the document has been altered.

Scope of this report

Covers peptide purity by HPLC-UV at 220 nm and a microbial screen, both recorded as Pass. The certificate also prints a By Mass figure whose basis the laboratory has not confirmed, so no net content is stated here.

Scope of this report

Covers the finished blend vial: peptide purity by HPLC-UV at 220 nm and a microbial screen, both recorded as Pass. It reports Selank and Semax together as a single analyte, so it establishes the purity of the blend but NOT the ratio between the two peptides. The certificate spells the second peptide “SEEMAX”; it is reproduced here as printed. The certificate also carries a By Mass figure whose basis the laboratory has not confirmed, so no net content is stated.

Scope of this report

Component-level report. Does not establish the identity, ratio, purity, sterility, or content of the finished blend vial.

Scope of this report

Component-level report. The laboratory states the sample was filtered prior to analysis due to floating insoluble particles. Does not establish the identity, ratio, purity, sterility, or content of the finished blend vial.

Scope of this report

The report measures content only: BPC-157 at 11.41 mg and TB-500 (TB4) at 10.72 mg, against a 10 mg + 10 mg label. It records NO purity figure, no microbial screen and no endotoxin testing, so nothing about those is claimed here. The document can be checked against Janoshik's own records with verification key PZ23I9KZHMPX.

Scope of this report

FTIR and HPLC for identification, purity, potency and composition, against a labeled content of 10 mg. The report states its own limits plainly: it does NOT provide information on particulate matter, microbial contamination or the presence of endotoxins. Commissioned by Peptide Global Co rather than by ASCND.

Scope of this report

FTIR and HPLC for identification, purity, potency and composition, against a labeled content of 10 mg. The report states that it does NOT cover particulate matter, microbial contamination or endotoxins. Commissioned by Peptide Global Co rather than by ASCND.

Scope of this report

FTIR and HPLC for identification, purity, potency and composition, against a labeled content of 10 mg. The report states that it does NOT cover particulate matter, microbial contamination or endotoxins. Commissioned by Peptide Global Co rather than by ASCND.

Scope of this report

Identity passed against a reference standard. This is the first purity and endotoxin figure published for KLOW; the content analysis beside it covers neither. Read the purity with the laboratory's own caveat, printed on the certificate: blend purity is the combined chromatographic area % of the peaks it identified as the intended components, not absolute mass purity, and it establishes neither individual component purity nor the ratio between them. Measured quantities are GHK-Cu 68.15 mg, BPC-157 15.17 mg, TB-500 12.68 mg and KPV 11.72 mg, which total 107.72 mg against the 80 mg the same certificate names as the amount. Endotoxin is 7.59 EU/mg — per milligram, not the per-vial figure other reports in this catalog print. One vial was tested. The lot number here, 206076380, is the content analysis's batch 2026076380 less one digit; nothing in either document establishes that the two are the same lot.

Scope of this report

The report states its own limit in its title: identity and amount, PEPTIDE PURITY NOT INCLUDED. Three vials were measured and vary between them — KPV 14.33 / 11.64 / 13.22 mg, BPC-157 11.43 / 9.32 / 10.27 mg, TB-500 (TB4) 12.84 / 10.33 / 11.73 mg, and GHK-Cu 64.42 / 52.07 / 59.16 mg. This document carries no purity, microbial or endotoxin figure of its own; the Vanguard certificate for lot 206076380 reports purity and endotoxin, and those lot numbers differ by one digit. Verification key ZAVQRJYXWPHD.

Scope of this report

Identity confirmed, appearance recorded as blue lyophilized powder, purity 99.77% / 99.78% / 99.75% across three vials. Measured net contents are GHK-Cu 58.22 / 54.02 / 56.12 mg, Thymosin Beta-4 12.08 / 19.36 / 19.75 mg and BPC-157 10.38 / 5.82 / 6.02 mg — totalling roughly 79-82 mg per vial, which brackets the 80 mg on the label. The split between the three components varies materially from vial to vial, so the blend ratio should be read as nominal rather than exact. Note also that the certificate names Thymosin Beta-4, of which TB-500 is a fragment.

Scope of this report

Three vials measured at 47.77, 48.70 and 47.56 mg GHK-Cu against a 50 mg label, with GHK content and copper content broken out separately, and purity of 99.467% / 99.462% / 99.471%. The report covers identity, amount and purity; it records no microbial or endotoxin testing. Verification key N2CNF4RPLJ4K.

Scope of this report

Content measured at 9.91 mg against a 10 mg label, purity 98.073%. The report covers identity, amount and purity only; it records no microbial screen and no endotoxin testing. Verification key R7IP8PGZ5MSI.

Scope of this report

Identity confirmed by LC-MS, purity 99.77% by HPLC-UV, net content 10.87 mg against a 10 mg label, appearance recorded as white lyophilized powder. Endotoxin testing was performed by Limulus Amebocyte Lysate assay under USP <85> and both replicates passed at an assay sensitivity of ≤0.05 EU/mL.